TX-FLUENCE
15.6.2021 13:02:13 CEST | Business Wire | Press release
Fluence by OSRAM (Fluence), a leading global provider of energy-efficient LED lighting solutions for commercial cannabis and food production, today released its RAZR Modular System, the company’s newest LED solution for vertical farmers featuring market-leading efficacies of 2.6 µmol/J under Fluence’s PhysioSpec™ BROAD R3 white spectrum.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210615005453/en/
Fluence’s years of experience collaborating with vertical farmers have proven PhysioSpec™ BROAD R3 is the optimal spectrum choice for crop propagation and full-cycle cultivation for a multitude of leafy greens, microgreens, herbs and other vegetables. Under Fluence’s BROAD R3 spectrum, the newest RAZR system is 18% more efficient than previous generations. The RAZR Modular System’s mechanical mounting and electrical wiring are also highly configurable and easily integrate into various racking styles. The system’s flexible design makes it uniquely suited for scale in a vertical farming environment.
“Vertical farmers are fueling some of the greatest innovations in modern crop production,” said David Cohen, CEO of Fluence. “By simplifying the food supply chain, vertical farms can deliver fresh, nutritional produce to localized regions. These intricate cultivation facilities typically require custom, multilayer racking systems with specialized LED lighting solutions that can optimize plant development through various growth stages. Our RAZR Modular System not only reduces overall operational expenses through its efficient and configurable fixtures, but also offers a proven spectrum for propagation and vertical cultivation for leafy greens, microgreens, herbs and other vegetables.”
Fluence distributes its RAZR Modular System to vertical farmers directly and through partners such as Ecopromt, a leading greenhouse consultancy. Ecopromt’s cultivation experts have designed a fully integrated cart system featuring the RAZR Modular System as well as a proprietary irrigation system. Ecopromt’s integrated cart system has been installed in multiple vertical farms throughout Europe and the U.S.
“Our team has been designing, developing and growing under the most advanced cart systems for vertical farming for nearly a decade,” said Tom Jönsson, head of sales for Ecopromt. “Ecopromt’s fully integrated system is easy to install and built to scale as a vertical farm grows. Combined with our irrigation system and configurable design, RAZR’s modular capabilities provide homogenous light distribution across crops, enabling growers to produce consistent, high-quality plants under some of the industry’s most efficient lighting technology.”
Based in Brooklyn, New York, aquaponic vertical farm Upward Farms leverages Fluence’s RAZR Modular System to optimize growth cycles for several microgreen and baby green variants through different stages of cultivation.
“The RAZR system is flexible, efficient and powerful, which allowed us to quickly and seamlessly integrate it into our grow stacks,” said Ben Silverman, CTO of Upward Farms. “RAZR’s modular nature allows us to tailor the lights to our system while increasing efficiency and reducing grow time.”
For more information about the RAZR Modular System and Fluence’s extended portfolio of LED solutions, visit www.fluence.science .
About Fluence by OSRAM
Fluence Bioengineering, Inc., a wholly-owned subsidiary of OSRAM , creates powerful and energy-efficient LED lighting solutions for commercial crop production and research applications. Fluence is a leading LED lighting supplier in the global cannabis market and is committed to enabling more efficient crop production with the world’s top vertical farms and greenhouse produce growers. Fluence global headquarters are based in Austin, Texas, with its EMEA headquarters in Rotterdam, Netherlands. For more information about Fluence, visit https://fluence.science .
About Upward Farms
Upward Farms is a USDA-Certified Organic aquaponic vertical farm located in Brooklyn, NY. Upward Farms uses a breakthrough approach that marries modern vertical farming with the ancient practice of aquaponics. This method utilizes fish to fertilize crops in a complete ecosystem that relies on the naturally occurring microbiome, which is the superpower that has sustained life for millions of years. Upward Farms is dedicated to healing the broken food system & reconnecting eaters with flavorful, nutritious, local food. To learn more about Upward Farms, visit www.eatupwardfarms.com .
About Ecopromt
Ecopromt is a family-owned business that works in the horticulture sector, specialized in fresh herbs but also focuses on research and development on other crops. Ecopromt offers consultation on growing and technical advice, with a business strategy of combining biology, chemistry and automation so that growers around the world can get more effective with their crops. Ecopromt with its main office in Sweden is an official reseller of Fluence by OSRAM lights and manufacturer of our own integrated cart systems. Ecopromt also have a branch office in Harrisonburg, Virginia where we offer similar services.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210615005453/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
